Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Emmaus Life Sciences Inc (EMMA)
Emmaus Life Sciences Inc (EMMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,803
  • Shares Outstanding, K 61,846
  • Annual Sales, $ 18,390 K
  • Annual Income, $ -10,630 K
  • 60-Month Beta 1.64
  • Price/Sales 0.24
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EMMA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.10
  • Most Recent Earnings $-0.01 on 11/13/23
  • Latest Earnings Date 03/29/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0736 +49.46%
on 02/07/24
0.1322 -16.79%
on 02/22/24
+0.0147 (+15.42%)
since 01/23/24
3-Month
0.0506 +117.39%
on 12/20/23
0.1350 -18.52%
on 11/30/23
+0.0100 (+10.00%)
since 11/22/23
52-Week
0.0506 +117.39%
on 12/20/23
0.4200 -73.81%
on 02/28/23
-0.2975 (-73.01%)
since 02/23/23

Most Recent Stories

More News
The Leading Emerging Markets For Market-Beating Gains in 2024

Emerging markets are expected to outperform over the next year and will be led by countries like Brazil and India, if for different reasons.

EEM : 40.60 (-0.05%)
EPI : 44.47 (-0.09%)
INCO : 63.43 (+0.11%)
VALE : 13.47 (-0.30%)
EWZ : 33.12 (-1.10%)
EWW : 66.53 (-1.00%)
SPY : 507.85 (+0.07%)
PSMT : 82.55 (+0.60%)
EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Reports Management Changes

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Reports Q2 2023 Financial Results

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...

EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...

EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Provides Interim Shipment Data

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended...

EMMA : 0.1100 (-16.79%)
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.1100 (-16.79%)
Dr. Niihara Meets with Local Indian Governor

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...

EMMA : 0.1100 (-16.79%)
Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...

EMMA : 0.1100 (-16.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1292
2nd Resistance Point 0.1233
1st Resistance Point 0.1167
Last Price 0.1100
1st Support Level 0.1042
2nd Support Level 0.0983
3rd Support Level 0.0917

See More

52-Week High 0.4200
Fibonacci 61.8% 0.2789
Fibonacci 50% 0.2353
Fibonacci 38.2% 0.1917
Last Price 0.1100
52-Week Low 0.0506

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar